The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Fortis; Janux Therapeutics
Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Jacqueline Vuky
Research Funding - Agendia (Inst); Arvinas (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); Exelixis (Inst); Fortis (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Rgenix (Inst)
 
David James VanderWeele
Consulting or Advisory Role - Clovis Oncology; Exelixis; Janssen
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation
 
Matthew Rettig
Stock and Other Ownership Interests - ARavalent; Oncovalent Therapeutics; Survalent
Consulting or Advisory Role - Ambrx; Amgen; Clovis Oncology; Roivant
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Elisabeth I. Heath
Honoraria - Bayer; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Dantari Pharmaceuticals; GlaxoSmithKline; GRAIL; Janssen; Myovant Sciences; Pfizer; Sanofi; Sapience Therapeutics
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Jiaoti Huang
Stock and Other Ownership Interests - Gencode; Genetron Health; KingMed Diagnostics; More Health; Omnitura; Optra SCAN; Sisu Pharmaceuticals; VetOncoRx; York Biotechnology
Honoraria - Abbvie; Genetron Health; KingMed Diagnostics
Consulting or Advisory Role - Gem Flower Healthcare
Research Funding - BioXcell; Fortis; Zenith Epigenetics
Travel, Accommodations, Expenses - Gem Flower Healthcare (I)
 
Nela Pawlowska
No Relationships to Disclose
 
Ryan Sinit
No Relationships to Disclose
 
Jill Abbey
Consulting or Advisory Role - Fortis; Virtuoso Therapeutics; Vivace Therapeutics
 
Bin Liu
Leadership - Fortis
Stock and Other Ownership Interests - Fortis
Consulting or Advisory Role - Fortis
Patents, Royalties, Other Intellectual Property - I am a inventor of patents related to CD46 targeting and CD46-binding human antibodies that are licensed to Fortis Therapeutics.
 
Marc Nasoff
No Relationships to Disclose
 
Andrew Dorr
Employment - SciQ (I)
Leadership - Cend Therapeutics; Circle Pharma; Curegenix; Delta TpX; Fortis; Phoenix Molecular Designs; Virtuoso Therapeutics; Vivace Therapeutics
Consulting or Advisory Role - BrightPath Biotheraputics; Cend Therapeutics; Circle Pharma; Curegenix; Delta TpX; Fortis; Phoenix Molecular Designs; PointPath.Biz; Secura Bio; Virtuoso Therapeutics; Vivace Therapeutics
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Fortis; Fortis; Janssen Oncology; Teon Therapeutics; Ultragenyx Pharmaceuticals
Travel, Accommodations, Expenses - Janssen